Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Eisterer, W; Piringer, G; DE Vries, A; Öfner, D; Greil, R; Tschmelitsch, J; Samonigg, H; Sölkner, L; Gnant, M; Thaler, J; Austrian Breast and Colorectal Cancer Study Group.
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Anticancer Res. 2017; 37(5):2683-2691 Doi: 10.21873/anticanres.11617 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz

Samonigg Hellmut

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

To evaluate feasibility and safety of neoadjuvant chemotherapy with capecitabine, oxaliplatin and bevacizumab followed by concomitant standard chemoradiation and surgical resection in patients with high-risk locally advanced rectal cancer. Magnetic resonance imaging (MRI)-defined high-risk cT3/4 rectal cancer patients were treated with 3 cycles of neoadjuvant chemotherapy with capecitabine (1,000 mg/m² twice daily days 1-14, 22-35, 43-56), oxaliplatin (130 mg/sqm on days 1, 22, 43) and bevacizumab (7.5 mg/kg on days 1, 22, 43) followed by capecitabine (825 mg/m² twice daily on radiotherapy days week 1-4) concomitantly with radiotherapy (1.8 Gy daily up to 45 Gy in 5 weeks) and surgical resection by total mesorectal excision. Feasibility, safety, response rate and postoperative morbidity were evaluated. Twenty-five patients were recruited. Median age was 62 years (range=24-78 years) and all patients had Eastern Cooperation Oncology Group (ECOG) performance status 0. From all patients, 79.2% finished neoadjuvant chemotherapy. Twenty patients underwent surgery. Pathologic complete remission rate, R0 resection and T-downstaging were achieved in 25%, 95% and 54.2% of the "intention to treat" (ITT) patients. The most common grade 3 adverse events (AEs) during neoadjuvant chemotherapy were diarrhea (16.6%) and mucositis (12.5%). In one patient, a grade 4 acute renal failure occurred (4.2%). During chemoradiation, skin reactions (5.3%) were the most common grade 3 AEs. Two major perioperative complications required re-intervention. Neoadjuvant chemotherapy with bevacizumab, capecitabine and oxaliplatin followed by concomitant standard chemoradiation is feasible in patients with high-risk locally advanced rectal cancer (LARC) and resulted in complete pathologic remission (pCR) rate of 25% and neoadjuvant chemotherapy completion rate of 80%. Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Find related publications in this database (using NLM MeSH Indexing)

Adult -

Aged -

Antineoplastic Agents - adverse effects

Antineoplastic Agents - therapeutic use

Antineoplastic Combined Chemotherapy Protocols - adverse effects

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

Bevacizumab - adverse effects

Bevacizumab - therapeutic use

Capecitabine - adverse effects

Capecitabine - therapeutic use

Chemoradiotherapy - adverse effects

Female -

Humans -

Magnetic Resonance Imaging -

Male -

Middle Aged -

Neoadjuvant Therapy -

Neoplasm Recurrence, Local -

Organoplatinum Compounds - adverse effects

Organoplatinum Compounds - therapeutic use

Oxaliplatin -

Rectal Neoplasms - diagnostic imaging

Rectal Neoplasms - drug therapy

Rectal Neoplasms - surgery

Rectal Neoplasms - therapy

Risk -

Treatment Outcome -

Young Adult -

Find related publications in this database (Keywords)

Neoadjuvant chemotherapy

rectal cancer

capecitabine

oxaliplatin and bevacizumab

© Med Uni Graz • Impressum